Peptides in the United States and UAE: One Week, Two Regulatory Signals

On 22 July 2026, Forbes asked whether peptides may soon become legal, and which companies were preparing to benefit. The timing made the question unusually useful. Within the next three days, regulators in the United States and the UAE supplied two very different answers.

On 23 and 24 July, the US Food and Drug Administration's Pharmacy Compounding Advisory Committee recommended six peptide substances for possible inclusion on the Section 503A bulks list. On 25 July, the Emirates Drug Establishment disclosed action involving 71 sources marketing, promoting or selling unapproved peptide products in the UAE. Fourteen establishments registered with local authorities were included, and 14 social media influencers were referred to the National Media Office.

Those events cover different laws and partly different substances. They do not amount to an American opening opposed by an Emirati ban. Their shared subject is a market that has already outrun the systems expected to govern it. Consumer demand, online promotion and cross-border supply have moved faster than human evidence, pharmaceutical controls and patient surveillance.

I have spent 13 years working in digital health, and this pattern is familiar. A promising category gathers attention. Commercial activity accelerates. The public language becomes more certain than the evidence. Then regulators, clinicians and responsible operators inherit the difficult work of establishing what can be supplied, by whom, under which controls, and with what record of patient outcomes.

Two Decisions That Should Be Read Carefully

The US committee supported BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. It rejected emideltide, also known as DSIP. The votes were advisory. They did not approve the six peptides as medicines, establish safety or efficacy, or add them immediately to the final federal list.

Section 503A provides a narrow route for qualifying patient-specific compounding. A favourable final decision could allow an eligible pharmacy to use a listed bulk substance when the other legal conditions are satisfied. It would not create ordinary product approval, wholesale manufacturing authority or a general right to advertise a peptide for recovery, longevity, inflammation or weight loss.

FDA must still consider the committee record and complete the required administrative process. It may accept selected recommendations, limit forms or routes, impose conditions, request more data or decline to change the list. There is no dependable completion date. Any business forecast that treats the committee vote as booked revenue rests on an unfinished legal event.

The UAE action addressed another point in the chain. According to reports carrying the Emirates Drug Establishment's statements, the identified products were promoted mainly for weight loss through websites, online marketplaces and social media accounts. Retatrutide was named specifically. It remains an investigational medicine and has no UAE marketing authorisation.

Retatrutide was absent from the seven substances considered by the US committee. This detail prevents a careless comparison between the two countries. The meaningful connection lies in market conduct: experimental or unapproved products can reach consumers through digital channels long before regulators recognise a lawful route for routine supply.

EDE also said it had found no circulation of the unapproved products inside licensed pharmaceutical warehouses under its supervision. That distinction matters. It points towards sellers and promoters operating outside authorised pharmaceutical channels, while inspections of compounding pharmacies were also under way. The signal is precise. Licence status, product registration, promotional conduct and supply route each matter.

The Evidence Remains the Hard Part

FDA's scientific reviewers recommended against adding all seven substances. Across the individual assessments, they found limited human data, uncertain product identity, inconsistent formulations, immunogenicity concerns and insufficient safety information. The committee reached a different policy judgement for six substances, yet the underlying evidence did not become stronger when the votes were counted.

BPC-157 offers the clearest example. It has a large public profile and a substantial animal-research narrative. FDA identified one small randomised ulcerative-colitis study involving 53 participants, with 46 completing it. Public reporting was inadequate for a confident assessment. The study used an enema formulation, while much online promotion concerns subcutaneous products for tendon, muscle and injury recovery.

For KPV, TB-500 and MOTS-c, FDA found no persuasive human evidence for the nominated compounded uses. Semax has a history of study and use outside the United States, especially in Russia, although the available record did not satisfy the standard FDA applied. Evidence for Epitalon remains sparse and methodologically weak. The conclusion I draw is straightforward: a possible compounding route cannot carry the clinical meaning of an approved-drug dossier.

The quality question begins even earlier. A peptide product must contain the correct sequence at the stated potency. It must be assessed for related substances, residual solvents, endotoxin, particulates and sterility where relevant. The method must suit the actual formulation. Stability data must support the container, storage conditions, shipping and beyond-use date. A supplier certificate has limited value when no independent release test confirms the batch.

The UAE Has Defined the Commercial Boundary

UAE Federal Decree-Law No. 38 of 2024 recognises licensed compound pharmacies and gives qualifying compounded products a specific exemption from the ordinary marketing-approval requirement. The same law prohibits improvised or unstudied formulations and products compounded for research, development or experimentation.

This creates a workable distinction for serious operators. Licensed compounding can exist within defined professional duties. An experimental vial promoted for human treatment through an influencer cannot rely on the words "research use only" as a shield. Regulators can examine its presentation, instructions, intended customer and actual route to market.

The UAE action also shows why digital distribution deserves its own control system. A website can cross borders. An influencer can turn an uncertain claim into apparent personal evidence. A payment provider, fulfilment service and messaging channel can create a functional health business without the visible premises people associate with a clinic or pharmacy. Each digital step generates a party who can be identified, assessed and held accountable.

The relevant questions become practical. Who imported the material? Where was the active ingredient synthesised and purified? Which entity holds the pharmacy and prescribing licences? Was the formulation authorised for this pathway? Can every dispensed order be linked to a patient and valid prescription? Which batch reached that person? What happens if a sterility result fails or a patient reports harm?

These questions describe the operating model that credible companies will need. They also explain why the frequently repeated estimate of a $3 billion peptide grey market should be handled carefully. I found no transparent public calculation behind it. At an average monthly spend of $150 to $300, annual sales of $3 billion would imply about 833,000 to 1.67 million continuous paying customers. The estimate may combine research chemicals, clinic services, telehealth fees and adjacent products. It is a signal of interest, not a reliable valuation base.

Where This Connects to My Work

I do not provide peptide therapy. My interest is in how people make safer, evidence-led health decisions.

My work with individuals is grounded in evidence-based integrative medicine. I combine conventional clinical care with movement science, nutrition, stress management, behavioural interventions and appropriate health data. A peptide conversation therefore starts with the person, the goal, the diagnosis, the quality of evidence and the alternatives already available. The attraction of a vial should never narrow a whole health story to one molecule.

As Senior Clinical Advisor to SPAN UAE, I also see this through social prescribing. SPAN UAE is building the country's first national network for a model that connects people to community activities and support for the practical, social and emotional factors affecting health. A link worker can help turn what matters to a person into a plan involving movement, peer support, nature, creative activity or volunteering. That wider pathway matters when online peptide claims appeal to people seeking recovery, confidence, weight management or renewed purpose.

CIGMA and its companion MOA extend this view into mental resilience. They can help people recognise stress, sustain useful habits and reach human or community support. Their role around an emerging treatment category is to support the person before and after a clinical decision, keep uncertainty visible and help concerns reach someone qualified to respond.

At EthicaLabs, the same issue becomes a governance test. Policy must reach marketing claims, supplier review, clinical workflow, consent, data use and escalation. A rule stored in a document has little force when an influencer overstates evidence, a new supplier enters fulfilment, or an adverse event remains trapped in customer support.

These strands meet in one principle: healthcare should widen the support around a person while tightening the controls around a product. Integrative medicine and social prescribing broaden the care pathway. CIGMA supports resilience and connection. EthicaLabs makes responsibility operational. They shape a response to peptide demand that begins with human need, respects clinical limits and gives every actor a clear documented duty of care.

The Opportunity Sits in Proof

The direct peptide sellers attract attention because their potential revenue is easy to imagine. I see durable value in the supporting layer: qualified active-ingredient supply, validated analytical testing, sterile production, prescription controls, batch provenance, pharmacovigilance and evidence-led patient monitoring.

Those capabilities remain useful across several regulatory outcomes. If FDA lists only one or two substances, they are needed. If the process takes years, they are needed. If enforcement tightens, they become more valuable. They can also serve approved medicines and other compounded products, which reduces dependence on a single regulatory bet.

Executives and investors should ask for evidence at operating level. They should inspect licences, source qualification, analytical methods, stability work, inspection history, prescription flow, claims review, adverse-event thresholds and recall records. They should model revenue against delay, restricted routes and rejection. A company that can answer with dated records has something worth assessing. Testimonials and search traffic cannot substitute for that record.

The United States and UAE have sent coherent signals when read at the right level. The US process shows that regulated access may expand through a narrow compounding mechanism. The UAE action shows active enforcement against unapproved products and promotion outside authorised channels. Both place greater weight on the same capability: proving how a health product travelled from evidence and ingredient to prescription, patient and outcome.

The #Ramyfications Worth Holding Onto

Peptides may develop into an important treatment category. That future still depends on final regulatory decisions, better human evidence and disciplined healthcare operations. Public attention has already arrived. Credible access will be earned more slowly.

The #Ramyfication worth holding onto: access becomes credible when every claim, vial, prescription, batch and patient outcome can be traced.